Glepaglutide for short bowel syndrome

Glepaglutide is  a GLP-2 analog in development for the treatment of Short Bowel Syndrome (SBS). FDA granted orphan drug designation applications to glepaglutide for the treatment of Short Bowel syndrome (SBS) in October 2017.

Short bowel syndrome is a severe condition with significant therapeutic needs

Short bowel syndrome (SBS) is a life-threatening and complex chronic severe condition associated with reduced or complete loss of intestinal function. The main underlying causes of SBS are major intestinal surgery following Crohn’s disease, ischemia, radiation damage and surgery in adults. .

It is estimated that 20,000-40,000 patients are affected by SBS in the U.S. and Europe. The most severely affected patients dependent on total parenteral nutrition also called home parenteral nutrition (TPN or HPN). That means that the small intestine cannot absorb nutrition nor fluids and will need to be delivered via bags of nutrition and fluids via a central venous catheter also known as a central line catheter . This requires them to be connected to infusion lines and pumps, which pose significant restrictions on a patient’s ability to engage in daily activities.

Glepaglutide is a long-acting GLP-2 analog

Patients living with SBS whom are dependent on HPN may suffer from several complications involving hydrational, renal and bone function.

Glepaglutide is being developed to alow patients to reduce their dependency on HPN.